Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers

Human Psychopharmacology

Volumn 28, Issue 3, 2013, Pages 281-286

  Sasada, Kazumi ^a   Iwamoto, Kunihiro ^a   Kawano, Naoko ^a   Kohmura, Kunihiro ^a   Yamamoto, Maeri ^a   Aleksic, Branko ^a   Ebe, Kazutoshi ^b   Noda, Yukihiro ^c   Ozaki, Norio ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Rd Management Section   (Japan)

^c MEIJO UNIVERSITY   (Japan)

Author keywords

cognitive function; driving performance; mirtazapine; sedative antidepressant; trazodone

Indexed keywords

ANTIDEPRESSANT AGENT; MIRTAZAPINE; PLACEBO; TRAZODONE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTINUOUS PERFORMANCE TEST; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRIVING ABILITY; EYE TRACKING; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; SOMNOLENCE; STANDARD; STANFORD SLEEPINESS SCALE; WISCONSIN CARD SORTING TEST;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; AUTOMOBILE DRIVING; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; SLEEP STAGES; TRAZODONE;

EID: 84878247340     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2321     Document Type: Article

References (38)

1. Bourin M, Briley, M,. 2004. Sedation, an unpleasant, undesirable and potentially dangerous side-effect of many psychotropic drugs. Hum Psychopharmacol 19: 135-139.
2. Brunnauer A, Laux G, Geiger E, Soyka M, Moller HJ,. 2006. Antidepressants and driving ability: results from a clinical study. J Clin Psychiatry 67: 1776-1781.
3. Brunnauer A, Laux G, David I, Fric M, Hermisson I, Moller HJ,. 2008. The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients. J Clin Psychiatry 69: 1880-1886.
4. Bryant SG, Ereshefsky L,. 1982. Antidepressant properties of trazodone. Clin Pharm 1: 406-417.
5. Callicott JH, Bertolino A, Mattay VS, et al,. 2000. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 10: 1078-1092.
6. Callicott JH, Egan MF, Mattay VS, et al,. 2003. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry 160: 709-719.
7. Chang CM, Wu EC, Chen CY, et al,. 2013. Psychotropic drugs and risk of motor vehicle accidents: a population-based case-control study. Br J Clin Pharmacol 75: 1125-1133.
8. Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L,. 1988. The Continuous Performance Test, Identical Pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res 26: 223-238.
9. Curran HV, Sakulsriprong M, Lader M,. 1998 Antidepressants and human memory: an investigation of four drugs with different sedative and anticholinergic profiles. Psychopharmacology (Berl) 95: 520-527.
10. Dassanayake T, Michie P, Carter G, Jones A,. 2011. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf 34: 125-156.
11. Deptula D, Pomara N,. 1990. Effects of antidepressants on human performance: a review. J Clin Psychopharmacol 10: 105-111.
12. Heaton RK,. 1981. The Wisconsin Card Sorting Test (Manual). Psychological Assessment Resources: Odessa, FL.
13. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC,. 1973. Quantification of sleepiness: a new approach. Psychophysiology 10: 431-436.
14. Iwamoto K, Takahashi M, Nakamura Y, et al,. 2008. The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: a double-blind crossover trial. Hum Psychopharmacol 23: 399-407.
15. Linden M, Westram A,. 2010. Prescribing a sedative antidepressant for patients at work or on sick leave under conditions of routine care. Pharmacopsychiatry 43: 1-6.
16. Mann JJ,. 2005. The medical management of depression. N Engl J Med 353: 1819-1834.
17. Meuleners LB, Duke J, Lee AH, Palamara P, Hildebrand J, Ng JQ,. 2011. Psychoactive medications and crash involvement requiring hospitalization for older drivers: a population-based study. J Am Geriatr Soc 59: 1575-1580.
18. Preskorn SH,. 1996. Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. Professional Communications: Caddo, OK.
19. Ramaekers JG,. 2003. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. J Clin Psychiatry 64: 20-29.
20. Ramaekers JG, Muntjewerff ND, Veggel LMAV, Uiterwijk MMC, O'Hanlon JF,. 1998. Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance in young, healthy volunteers. Hum Psychopharmacol 13: 87-97.
21. Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T,. 2002. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 22: 511-515.
22. Ridout F, Meadows R, Johnsen S, Hindmarch I,. 2003. A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol 18: 261-269.
23. Roth AJ, McCall WV, Liguori A,. 2011. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res 20: 552-558.
24. Sadock BJ, Sadock VA, Sussman N, Cancro R,. 2005. Kaplan and Sadock's Pocket Handbook of Psychiatric Drug Treatment. Lippincott, Williams & Wilkins: Philadelphia, PA.
25. Sakulsripong M, Curran HV, Lader M,. 1991. Does tolerance develop to the sedative and amnesic effects of antidepressants? A comparison of amitriptyline, trazodone and placebo. Eur J Clin Pharmacol 40: 43-48.
26. Sansone RA, Sansone LA,. 2009. Driving on antidepressants: cruising for a crash? Psychiatry (Edgmont) 6: 13-16.
27. Serretti A, Calati R, Goracci A, Di Simplicio M, Castrogiovanni P, De Ronchi D,. 2010. Antidepressants in healthy subjects: what are the psychotropic/psychological effects? Eur Neuropsychopharmacol 20: 433-453.
28. Shen J, Moller HJ, Wang X, Chung SA, Shapiro GK, Li X, Shapiro CM,. 2009. Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients. J Clin Psychiatry, 70, 370-377.
29. Takahashi M, Iwamoto K, Kawamura Y, et al,. 2010. The effects of acute treatment with tandospirone, diazepam, and placebo on driving performance and cognitive function in healthy volunteers. Hum Psychopharmacol 25: 260-267.
30. Theunissen EL, Vermeeren A, van Oers AC, van Maris I, Ramaekers JG,. 2004. A dose-ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo. Clin Exp Allergy 34: 250-258.
31. Uchiyama Y, Ebe K, Kozato A, Okada T, Sadato N,. 2003. The neural substrates of driving at a safe distance: a functional MRI study. Neurosci Lett 352: 199-202.
32. van Laar MW, Volkerts ER, Verbaten MN, Trooster S, van Megen HJ, Kenemans JL,. 2002. Differential effects of amitriptyline, nefazodone and paroxetine on performance and brain indices of visual selective attention and working memory. Psychopharmacology (Berl) 162: 351-363.
33. Veldhuijzen DS, Kenemans JL, van Wijck AJ, Olivier B, Kalkman CJ, Volkerts ER,. 2006. Acute and subchronic effects of amitriptyline on processing capacity in neuropathic pain patients using visual event-related potentials: preliminary findings. Psychopharmacology (Berl) 183: 462-470.
34. Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ,. 2005. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 19: 137-146.
35. Verster JC, Roth T,. 2012a. Drivers can poorly predict their own driving impairment: a comparison between measurements of subjective and objective driving quality. Psychopharmacology (Berl) 219: 775-181.
36. Verster JC, Roth T,. 2012b. Predicting psychopharmacological drug effects on actual driving performance (SDLP) from psychometric tests measuring driving-related skills. Psychopharmacology (Berl) 220: 293-301.
37. Wezenberg E, Sabbe BG, Hulstijn W, Ruigt GS, Verkes RJ,. 2007. The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions. J Psychopharmacol 21: 579-587.
38. Wingen M, Bothmer J, Langer S, Ramaekers JG,. 2005. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 66: 436-443.